Liver transplant immunosuppression during the covid-19 pandemic.

Inmunosupresión en el trasplante hepático en la era covid-19.

Journal

Gastroenterologia y hepatologia
ISSN: 0210-5705
Titre abrégé: Gastroenterol Hepatol
Pays: Spain
ID NLM: 8406671

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 13 05 2020
revised: 27 05 2020
accepted: 07 06 2020
pubmed: 11 7 2020
medline: 21 10 2020
entrez: 11 7 2020
Statut: ppublish

Résumé

SARS-CoV-2 infection has produced a pandemic with serious consequences for our health care system. Although liver transplant patients represent only a minority of the population, the hepatologists who follow these patients have tried to coordinate efforts to produce a protocol the management of immunosuppression during SARS-CoV-2 infection. Although there are no solid studies to support general recommendations, experiences with other viral infections (hepatitis C, cytomegalovirus) suggest that management of immunosuppression without mycophenolate mofetil or m-Tor inhibitors (drugs that are also associated with leukopenia and lymphopenia) may be beneficial. It is also important to pay attention to possible drug interactions, especially in the case of tacrolimus, with some of the treatments with antiviral effect given in the context of COVID 19 (lopinavir/ritonavir, azithromycin). Finally, the immunosuppressive effect of immunomodulating drugs (tocilizumab and similar) administered to patients with severe lung disease should be taken into account. The mechanisms of action of the different immunosuppressive drugs are reviewed in this article, as well as their potential effect on SARS-CoV-2 infection, and suggests guidelines for the management of immunosuppression.

Identifiants

pubmed: 32646657
pii: S0210-5705(20)30215-6
doi: 10.1016/j.gastrohep.2020.06.003
pmc: PMC7290227
pii:
doi:

Substances chimiques

Antiviral Agents 0
Calcineurin Inhibitors 0
Glucocorticoids 0
Immunosuppressive Agents 0
Everolimus 9HW64Q8G6G
MTOR protein, human EC 2.7.1.1
TOR Serine-Threonine Kinases EC 2.7.11.1
Mycophenolic Acid HU9DX48N0T
Sirolimus W36ZG6FT64

Types de publication

Journal Article Review

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

457-463

Informations de copyright

Copyright © 2020 Elsevier España, S.L.U. All rights reserved.

Références

World J Hepatol. 2015 Jun 8;7(10):1355-68
pubmed: 26052381
Ther Drug Monit. 2016 Oct;38(5):640-5
pubmed: 27310199
Drug Discov Ther. 2020;14(1):58-60
pubmed: 32147628
Cytokine. 2018 Apr;104:8-13
pubmed: 29414327
Immunity. 2016 Jun 21;44(6):1379-91
pubmed: 27287409
J Innate Immun. 2020;12(1):4-20
pubmed: 31610541
Nat Cell Biol. 2017 Sep 28;19(10):1131
pubmed: 28960201
Clin Immunol. 2020 Jun;215:108448
pubmed: 32353634
Gastroenterol Hepatol. 2011 Jun-Jul;34(6):422-7
pubmed: 21458889
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Clin Exp Immunol. 2004 Apr;136(1):95-103
pubmed: 15030519
J Virol. 2005 Feb;79(3):1943-7
pubmed: 15650220
Transplantation. 2018 Feb;102(2S Suppl 1):S50-S59
pubmed: 29369973
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Blood. 2010 Apr 15;115(15):2989-97
pubmed: 20103781
Asian Pac J Allergy Immunol. 2020 Mar;38(1):10-18
pubmed: 32134278
Lancet. 2020 Feb 29;395(10225):683-684
pubmed: 32122468
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Gastroenterol Hepatol. 2014 Oct;37(8):480-91
pubmed: 25060591
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
J Infect Dis. 2006 Mar 15;193(6):792-5
pubmed: 16479513
J Pharm Anal. 2020 Apr;10(2):102-108
pubmed: 32282863
Emerg Infect Dis. 2006 Dec;12(12):1834-40
pubmed: 17326933
Hepatology. 2020 Jul;72(1):287-304
pubmed: 32298473
Autoimmun Rev. 2020 Jul;19(7):102567
pubmed: 32376392
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Clin Infect Dis. 2019 Mar 5;68(6):984-992
pubmed: 30060038
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
J Immunol. 2008 Oct 15;181(8):5490-500
pubmed: 18832706
Nat Rev Drug Discov. 2020 Mar;19(3):149-150
pubmed: 32127666
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776
pubmed: 32054787
J Virol. 2010 Nov;84(21):11336-49
pubmed: 20686038
Nat Rev Microbiol. 2009 Jun;7(6):439-50
pubmed: 19430490
J Infect. 2013 Dec;67(6):606-16
pubmed: 24096239
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Chemotherapy. 2011;57(1):56-61
pubmed: 21282947
Clin Liver Dis. 2013 Feb;17(1):129-39
pubmed: 23177289
Drug Discov Today. 2013 Oct;18(19-20):969-83
pubmed: 23684571
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
J Cell Physiol. 2019 Mar;234(3):2143-2151
pubmed: 30146782
Hepatology. 2012 Jun;55(6):1673-83
pubmed: 22213147
Exp Biol Med (Maywood). 2009 Oct;234(10):1117-27
pubmed: 19546349
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):532-533
pubmed: 32278366
Nat Rev Dis Primers. 2019 Mar 14;5(1):18
pubmed: 30872586
Int J Antimicrob Agents. 2020 Jun;55(6):105982
pubmed: 32305588
Antiviral Res. 2002 Jul;55(1):107-16
pubmed: 12076755
Crit Rev Oncol Hematol. 2005 Oct;56(1):23-46
pubmed: 16039869
PLoS Pathog. 2011 Oct;7(10):e1002331
pubmed: 22046132
Crit Care Med. 2014 Feb;42(2):313-21
pubmed: 24105455
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
N Engl J Med. 2003 Dec 18;349(25):2431-41
pubmed: 14681510
Hepatology. 2013 Nov;58(5):1824-35
pubmed: 23532679
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9
pubmed: 32105090
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Transplantation. 2018 Jul;102(7):1075-1084
pubmed: 29620612
J Infect Dis. 2016 Apr 1;213(7):1180-8
pubmed: 26597256
Am J Transplant. 2020 Jul;20(7):1800-1808
pubmed: 32330343
J Am Acad Dermatol. 2020 Jul;83(1):e65
pubmed: 32339701
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Lancet Infect Dis. 2009 May;9(5):291-300
pubmed: 19393959

Auteurs

Xavier Forns (X)

Unidad de Hepatitis Víricas y Unidad de Trasplante Hepático, Servicio de Hepatología, Hospital Clínic. Universitat de Barcelona, IDIBAPS, CIBERehd, Barcelona, España.

Miquel Navasa (M)

Unidad de Hepatitis Víricas y Unidad de Trasplante Hepático, Servicio de Hepatología, Hospital Clínic. Universitat de Barcelona, IDIBAPS, CIBERehd, Barcelona, España. Electronic address: mnavasa@clinic.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH